Pharmacokinetics and Disposition

European Journal of Clinical Pharmacology

, Volume 60, Issue 4, pp 265-268

First online:

Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays

  • P. T. Daley-YatesAffiliated withGlaxoSmithKline Research & Development, Clinical Pharmacology & Discovery Medicine Email author 
  • , R. L. KunkaAffiliated withGlaxoSmithKline Research & Development
  • , Y. YinAffiliated withGlaxoSmithKline Research & Development
  • , S. M. AndrewsAffiliated withGlaxoSmithKline Research & Development
  • , S. CallejasAffiliated withGlaxoSmithKline Research & Development
  • , C. NgAffiliated withGlaxoSmithKline Research & Development

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access



To compare the systemic exposure for intranasal mometasone furoate (MF) and fluticasone propionate (FP) aqueous nasal sprays (ANS) in terms of serum and urinary cortisol parameters and plasma pharmacokinetics.


Twelve healthy subjects completed this three-way, cross-over study. They received FPANS (50 μg/spray), MFANS (50 μg/spray) or placebo ANS, eight sprays per nostril every 8 h for 4 days. Cortisol measurements were made at baseline and day 4. FP and MF plasma concentrations were also measured on day 4.


MFANS produced similar mean plasma AUC (123 pmol/l h) to FPANS (112 pmol/l h). Despite the use of high doses, necessary to generate adequate pharmacokinetic data, only minor reductions in cortisol parameters were found, with no difference between FPANS and MFANS.


FP and MF have similar and very low systemic bioavailability when administered intranasally using a high-dose regimen. It is therefore unlikely that therapeutic doses of intranasal FP or MF will produce dissimilar or significant degrees of systemic exposure or systemic effects.


Fluticasone propionate Mometasone furoate Nasal bioavailability